Amoxicillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Amoxicillin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Amoxicillin is a beta-lactam antibiotic originally used for bacterial infections such as urinary tract infection, otitis media, pharyngitis and bacterial pneumonia. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but no clinical trials and no publications support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Urinary tract infection, infectious otitis media, streptococcal infection, bacterial pneumonia, pharyngitis (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Amoxicillin is known to be a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, and its efficacy in bacterial infections is well established.
For the top-ranked prediction, no mechanistic link could be identified. Polyclonal hyperviscosity syndrome is driven by elevated immunoglobulins and has no known antibiotic-responsive pathway. The high score (99.63%) is a graph-based inference only. Several other top-ranked predictions have the same score pattern (for example hyperamylasemia at 99.63% and congenital analbuminemia at 99.59%), and also lack a plausible mechanism. This suggests that the score alone should not be treated as evidence of efficacy.
Among the other predictions reviewed, two are more biologically plausible because they are bacterial or infection-related:
- Epiglottitis (score 98.70%, rank 10): usually caused by Haemophilus influenzae and other respiratory bacteria, close to the approved ENT indications (pharyngitis, otitis media). Beta-lactamase production limits amoxicillin use, and standard empirical therapy is a third-generation cephalosporin.
- Septicemic plague (score 99.13%, rank 8): beta-lactams show in vitro and animal activity against Yersinia, but standard plague treatment is an aminoglycoside, fluoroquinolone or tetracycline, and there is no human trial evidence for amoxicillin.
Clinical Trial Evidence
Currently no related clinical trials registered for polyclonal hyperviscosity syndrome.
For reference, the only trial retrieved for any of the leading predictions (monoclonal gammopathy and congenital hematological disorder) is below. It addresses fever in neutropenic cancer patients, not these conditions, and was graded as only indirectly relevant.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00062231 | Phase NA | Terminated | 351 | Moxifloxacin alone vs ciprofloxacin plus amoxicillin/clavulanic acid as oral empirical therapy for fever in low-risk neutropenic cancer patients |
Literature Evidence
Currently no related literature available for polyclonal hyperviscosity syndrome.
For reference, the most informative publications retrieved for the other leading predictions are listed below. None is an RCT.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8203841 | 1994 | Animal study | Antimicrob Agents Chemother | Amoxicillin was active in vitro and in a mouse model of Yersinia pestis infection, compared with other antibiotics (septicemic plague) |
| 21628541 | 2011 | In vitro study | Antimicrob Agents Chemother | Antibiotics commonly used for plague tested against intracellular Y. pestis (septicemic plague) |
| 37730165 | 2023 | Review | Infect Dis Now | Antimicrobial treatment guidance for ENT infections (epiglottitis) |
| 29290238 | 2017 | Review | Arch Pediatr | Antibiotic treatment of paediatric ENT infections, including when not to prescribe (epiglottitis) |
| 15960127 | 2005 | Case report | Acta Otorrinolaringol Esp | Base-of-tongue actinomycosis resolved after drainage and one month of oral amoxicillin (epiglottitis) |
| 3957763 | 1986 | Case report | J Am Vet Med Assoc | Bubonic plague in a cat treated successfully with amoxicillin and streptomycin (septicemic plague) |
| 20516363 | 2010 | Case report | Ann Pharmacother | Amoxicillin-induced hemolytic anemia in a child with glucose-6-phosphate isomerase deficiency (safety signal) |
Singapore Market Information
Amoxicillin has 20 valid single-ingredient registrations in Singapore and no cancelled ones. The licence records contain no approved indication text. The five main authorizations are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN00213P | APO-AMOXI CAPSULE 250 mg | Capsule | Not recorded |
| SIN06951P | MOXIPEN CAPSULE 250 mg | Capsule | Not recorded |
| SIN11300P | PULMOXYL DRY SYRUP 125 mg/5ml | Syrup | Not recorded |
| SIN03931P | BETAMOX GRANULES 250 mg/5 ml | Granules for suspension | Not recorded |
| SIN01607P | AMOXAPEN 250 CAPSULE 250 mg | Capsule | Not recorded |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.
- Contraindication-related disease associations (knowledge graph, not label text): long QT syndrome, torsades de pointes, ventricular tachycardia, liver failure, liver disease, cholestasis, kidney disease, porphyria, Clostridium difficile colitis, myasthenia gravis, osteoporosis, bone fracture, gallbladder disease, and infectious mononucleosis. These should be verified against the official label.
- Drug Interactions (100 interactions found; examples):
- Major: methotrexate; live cholera vaccine (Vibrio cholerae CVD 103-HgR)
- Moderate: doxycycline, minocycline, demeclocycline, ethinylestradiol, estradiol, anisindione, dicoumarol, mycophenolate mofetil, entecavir, balsalazide, and several probiotics (Lactobacillus acidophilus, Bifidobacterium longum infantis)
- Minor: allopurinol, amiloride, azithromycin, clarithromycin, erythromycin
- Safety signal from the literature: one case report of amoxicillin-induced hemolytic anemia in a child with glucose-6-phosphate isomerase deficiency.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication, polyclonal hyperviscosity syndrome, has no clinical trials, no publications and no plausible mechanism. The high TxGNN score is a computational result only (Evidence Level L5). Amoxicillin is widely marketed in Singapore, so availability is not the limiting factor; the lack of evidence is.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a mechanistic rationale connecting a cell-wall-active antibiotic to hyperviscosity
- Package insert warnings and contraindications from the HSA, to complete safety screening
- Approved indication text for the Singapore licences
- If a repurposing direction is still wanted, consider re-prioritising the infection-related predictions (epiglottitis, septicemic plague) for a focused literature review, since they have biologically plausible links, though they are not supported by RCTs and standard therapy already uses other agents
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.